Glp 1 peptides10

Retatrutide vs Tirzepatide: Key Differences, Results & Side Effects (2026 Data)

Published May 20, 2026Updated October 19, 2026
Quick Brief

Retatrutide vs tirzepatide head-to-head in 2026: weight loss results (28.7% vs 20.9%), side effects, dosing, cost, FDA status, and which one wins.

Retatrutide vs Tirzepatide: Key Differences, Results & Side Effects (2026 Data)
Retatrutide - R-30

Procurement

Retatrutide - R-30

In StockShips from USA
$125.00$250.00
Get R-30

Retatrutide wins on weight loss numbers. 28.7% average body weight reduction in the TRIUMPH-4 Phase 3 trial (people with obesity and knee osteoarthritis, counting those who stayed on treatment) vs tirzepatide's 20.9% in SURMOUNT-1. In TRIUMPH-1, the main obesity trial, 12 mg averaged 28.3% at 80 weeks among people who stayed on treatment, or 25.0% counting everyone. But tirzepatide is FDA-approved today, available at pharmacies, and covered by insurance for millions of people. Retatrutide isn't. That gap defines every decision between these two drugs in 2026.

Last Updated October 19, 2026
28.7%Retatrutide TRIUMPH-4 Weight Loss
20.9%Tirzepatide SURMOUNT Weight Loss
3 vs 2Receptor Targets (Triple vs Dual)
FDAOnly Tirzepatide Is Approved

🔑 Key Takeaways

  • Retatrutide is a triple GLP-1/GIP/glucagon agonist; tirzepatide is a dual GLP-1/GIP agonist, the glucagon receptor is the key differentiator
  • Retatrutide produces ~4-6 percentage points more weight loss on average in like-for-like comparisons (TRIUMPH-1 vs SURMOUNT-1); no head-to-head result exists yet
  • Tirzepatide (Mounjaro/Zepbound) is FDA-approved and commercially available; retatrutide is not FDA-approved and nothing has been filed yet; Lilly plans to submit in Q1 2027
  • Retatrutide has stronger liver fat reduction and may better preserve lean mass due to the glucagon component
  • Side effect profiles are similar, GI symptoms dominate both, but retatrutide shows slightly higher heart rate elevation
  • For maximum weight loss potential: retatrutide. For proven, accessible treatment today: tirzepatide.

This guide covers the mechanism differences that actually matter, the clinical data side by side, side effects compared, dosing protocols for both, how to choose based on your situation, and what the availability gap means for people who can't wait for FDA approval.

How They Work: The Receptor Difference That Changes Everything

Both drugs are injectable once-weekly peptides that mimic natural gut hormones in the GLP-1 family. Both suppress appetite, slow gastric emptying, and stimulate insulin release. The difference is a third receptor.

Tirzepatide targets two receptors:

  • GLP-1 (Glucagon-like peptide-1), slows gastric emptying, suppresses appetite, stimulates glucose-dependent insulin release
  • GIP (Glucose-dependent insulinotropic polypeptide), improves insulin sensitivity, has direct effects on adipose tissue metabolism, enhances the GLP-1 effect

Retatrutide adds a third:

  • GLP-1, same mechanisms as tirzepatide
  • GIP, same mechanisms as tirzepatide
  • Glucagon receptor, increases energy expenditure through thermogenesis, promotes fat oxidation directly, reduces hepatic (liver) fat significantly, and may help preserve lean muscle mass during rapid weight loss

The glucagon component is where retatrutide's additional weight loss comes from. Glucagon accelerates fat burning beyond what appetite suppression and insulin sensitization alone achieve. Phase 2 data showed retatrutide reducing liver fat substantially more than expected from weight loss alone, with the glucagon pathway likely driving the extra benefit. This is particularly relevant for people with NAFLD or metabolic syndrome alongside obesity. The retatrutide liver fat data goes into the mechanism in more detail.

Why the glucagon receptor matters

Historically, glucagon was considered problematic in weight loss drugs because it raises blood sugar. Retatrutide solves this by combining glucagon activation with strong GLP-1 and GIP signaling that counteract the glucose-raising effect. The net result is fat oxidation and thermogenesis without meaningful glucose dysregulation, giving the drug a metabolic advantage that dual agonists simply can't replicate.

Clinical Trial Data: Head-to-Head Numbers

No direct head-to-head trial has been published. The comparison below draws from separate trials with different populations and durations, so interpret the numbers with that caveat in mind.

Metric
Retatrutide
Tirzepatide
Trial name (key)
SURMOUNT-1 (Phase 3)
Max weight loss (highest dose)
28.7% at 68 weeks (TRIUMPH-4, stayed on treatment); 28.3% at 80 weeks (TRIUMPH-1, stayed on treatment), 25.0% counting everyone
20.9% at 72 weeks counting everyone (22.5% among those who stayed on treatment)
Phase 2 max weight loss
24.2% at 48 weeks (12mg)
11.3 kg at 26 weeks (15mg, phase 2 in type 2 diabetes)
Meta-analysis % weight change
-23.77% (MD)
-16.79% (MD)
Meta-analysis absolute weight change
-16.34 kg
-11.82 kg
Liver fat reduction
Significant (glucagon-driven)
Significant (weight-loss-driven)
Lean mass preservation
Not shown to be better: lean share of loss similar to other incretin drugs (phase 2 DXA substudy)
Standard (similar to other GLP-1s)
FDA approval status
Not approved; Phase 3 results in, FDA filing planned Q1 2027
Approved (Mounjaro/Zepbound)
Cardiovascular outcome trial
TRIUMPH-Outcomes ongoing (to 2029); TRIUMPH-3 heart results inconclusive
SURPASS-CVOT: non-inferior to dulaglutide on heart events (HR 0.92)

A 2025 network meta-analysis (Salhab et al., PMC) comparing 12 clinical trials found retatrutide achieved statistically superior absolute and percentage weight reduction compared to tirzepatide across all trials analyzed (p < 0.0001). The absolute difference of approximately 4-5 kg in favor of retatrutide was consistent across subgroups.

Side Effects Compared

The side effect profiles of both drugs are dominated by gastrointestinal symptoms, because both activate GLP-1 receptors in the gut and slow gastric emptying. The differences are in magnitude and a few drug-specific effects.

Side Effect
Retatrutide
Tirzepatide
Nausea
42.4% (12 mg, TRIUMPH-1)
~25-45% (highest dose)
Vomiting
~20-30%
~9-25%
Diarrhea
~20-30%
~20-30%
Constipation
26.1% (12 mg, TRIUMPH-1)
~16-29%
Heart rate increase
Dose-dependent rise, peaked ~week 24 then eased (phase 2)
+2-4 bpm
Gallbladder disease
Yes (similar to class)
Yes (~1-3%)
Hair loss
Yes (weight-loss-driven)
Yes (weight-loss-driven)
Muscle loss
Not shown to be less; lean share of loss similar to other incretin drugs
About a quarter of weight lost was lean mass (SURMOUNT-1 DXA substudy)
Black box warning
Thyroid C-cell tumors (class)
Thyroid C-cell tumors (class)

For a complete frequency-by-dose breakdown see the retatrutide side effects guide and the tirzepatide side effects guide. Retatrutide's GI side effect burden is generally higher than tirzepatide at equivalent weight-loss doses, more nausea and vomiting, particularly during dose escalation. The heart rate elevation is also more pronounced with retatrutide, reflecting glucagon receptor activation's cardiovascular effects. Both differences are manageable with proper escalation schedules but should be expected upfront.

A lean mass advantage is often claimed but not proven. In a phase 2 DXA substudy, retatrutide's lean loss was not disproportionate to fat loss, about what other incretin drugs show, and no trial has compared muscle loss between the two drugs. For users concerned about muscle preservation during weight loss, protein intake and resistance training matter more than the drug choice.

Dosing Comparison

Phase
Retatrutide
Tirzepatide
Starting dose
2 mg once weekly
2.5 mg once weekly
Escalation schedule
Every 4 weeks
Every 4 weeks
Intermediate doses
2mg, 4mg, 6mg, 9mg (phase 3 steps)
2.5mg, 5mg, 7.5mg, 10mg, 12.5mg
Max approved/trial dose
12 mg (Phase 3)
15 mg (Zepbound)
Injection type
Subcutaneous, once weekly
Subcutaneous, once weekly
Can you hold at a dose?
Yes, do not escalate if GI burden is high
Yes, standard practice

Both drugs use the same escalation principle: start low, go slow, hold whenever GI side effects are present. Neither drug requires hitting the maximum dose to achieve significant weight loss. Many users achieve their target weight on intermediate doses and maintain there indefinitely.

Onset of Action: How Fast Each One Works

Both drugs produce noticeable appetite changes within the first week, but the full effect builds over months. The realistic timelines:

Milestone
Tirzepatide
Retatrutide
Appetite suppression starts
2–4 days after first dose
2–4 days after first dose
First measurable weight loss
Week 2–3
Week 2–3
~5% body weight lost
Around week 12
Around week 8–10
~10% body weight lost
Around week 24
Around week 16–20
~15% body weight lost
Around week 48 (max dose)
Around week 32–36
Trial peak weight loss
~20.9% at 72 weeks (SURMOUNT-1)
~28.7% at 68 weeks (TRIUMPH-4)

Retatrutide looks faster at most milestones. The gap widens at higher doses: by week 24, the 12 mg group in the phase 2 trial had already lost 17.5% on average (separate trials, so read it as a direction). For the full timeline see how long retatrutide takes to work and the tirzepatide timeline guide.

Cost: What You'll Actually Pay in 2026

Price is where the two drugs diverge sharply. Tirzepatide has retail pricing, insurance pathways, and compounding options. Retatrutide has none of that: until approval, it is clinical-trial only or bought as a vial from a peptide vendor. Here is how much retatrutide costs that way.

Channel
Tirzepatide (Mounjaro / Zepbound)
Retatrutide (R-10 / R-30)
Retail pharmacy (cash)
~$1,000–1,300/month
Not available
With insurance coverage
$25–550/month copay
Not applicable
LillyDirect direct-to-patient
$299–449/month (vials or pens; the $449 tier for 7.5–15 mg needs a refill within 45 days), October 2026
Not available
Telehealth compounded
~$200–400/month
Not legal: FDA says retatrutide can't be compounded
Research peptide vendor
T-10: ~$90 per 10mg vial
R-10: $100 per 10mg vial ($50 with code PEPTIDEDECK)
R-30: $250 per 30mg vial ($125 with code)
Effective cost per kg lost
~$50–80/kg
~$15–35/kg (research-grade)

On a per-kg-lost basis, research-grade retatrutide is dramatically cheaper than even compounded tirzepatide — but the trade-off is regulatory uncertainty and no clinical oversight. For the cheapest pharmacy-route option, see cheapest tirzepatide and the tirzepatide cost without insurance breakdown. For research-grade retatrutide pricing, see the retatrutide cost guide.

Availability in 2026: The Practical Reality

This is where the comparison becomes less academic and more real.

Tirzepatide availability

  • FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity)
  • Available at major US pharmacies with a prescription — see how to get tirzepatide in 2026
  • Covered by many insurance plans for eligible diagnoses
  • Compounded versions available through telehealth during shortage periods
  • Research-grade available from peptide vendors as T-10

Retatrutide availability

  • Main Phase 3 trials have reported (TRIUMPH-1 to -4); Lilly plans to file with the FDA in Q1 2027 — track the retatrutide FDA approval timeline
  • Not yet FDA-approved; no commercial pharmacy availability
  • The TRIUMPH trials are no longer recruiting (see retatrutide clinical trials), and Lilly's free, physician-requested early access program covers only a narrow group of patients
  • Sold by peptide vendors as R-10 (10mg) and R-30 (30mg) vials: see retatrutide for sale for current prices, or where to buy retatrutide to compare vetted vendors
  • FDA says retatrutide can't legally be compounded, has warned telehealth firms offering it, and advises consumers not to buy unapproved retatrutide; Lilly has sued sellers

How to Choose Between Them

Choose tirzepatide if:

  • You want an FDA-approved option with full prescribing infrastructure
  • You have insurance coverage that will offset the cost
  • Your cardiovascular history warrants the backing of published CVOT data (SURPASS-CVOT)
  • You want the most tested and well-understood GLP-1 option currently available
  • You've previously tolerated a GLP-1 and want proven dose-escalation protocols

Choose retatrutide if:

  • Maximum weight loss is the primary goal and the extra 4-6 percentage points matter to you
  • You have significant liver fat (NAFLD/NASH), the glucagon component provides additional hepatic benefit
  • Lean mass preservation during weight loss is important (athletes, active users)
  • You've plateaued or had suboptimal results on tirzepatide or semaglutide
  • You're accessing via research peptide channels and want the most potent available option

Switching From Tirzepatide to Retatrutide

This is increasingly relevant as retatrutide access grows. The practical switching protocol:

  • Take the last tirzepatide dose, then wait one full week (the standard weekly injection interval)
  • Start retatrutide at 2 mg regardless of what tirzepatide dose you were on
  • Do not attempt to dose-match, retatrutide is a different molecule with different potency
  • Expect some GI re-adjustment, even if you were fully tolerant of tirzepatide
  • Escalate on the standard 4-week schedule; don't rush to higher doses because you "know" GLP-1s

The switch is generally well tolerated. The extra GI burden in the first 2-4 weeks reflects retatrutide's higher potency, not intolerance. Most people who were fully adapted to tirzepatide adapt to retatrutide within 4-8 weeks. Some users instead try a microdosing protocol to soften the GI re-adjustment.

Bottom Line: Side-by-Side Verdict

Question
Winner
Why
Most weight loss in trials?
Retatrutide
28.3% vs 22.5% among people who stayed on treatment; 25.0% vs 20.9% counting everyone (TRIUMPH-1 vs SURMOUNT-1)
Fastest weight loss?
Retatrutide
Hits 10% loss ~4–8 weeks sooner
Best for liver fat (NAFLD/NASH)?
Retatrutide
Glucagon component drives extra hepatic fat reduction
Best for lean mass preservation?
Not proven
No trial shows retatrutide spares more muscle; lean share of loss looks similar
FDA-approved + available?
Tirzepatide
Mounjaro/Zepbound approved; retatrutide not yet filed (planned Q1 2027)
Insurance coverage?
Tirzepatide
Covered for eligible diagnoses; retatrutide isn't
Cardiovascular outcome data?
Tirzepatide
SURPASS-CVOT met non-inferiority vs dulaglutide; TRIUMPH-Outcomes ongoing
Lowest GI burden at peak dose?
Tirzepatide
~25–45% nausea vs 42.4% on retatrutide 12 mg (TRIUMPH-1)
Lowest heart-rate impact?
Tirzepatide
+2–4 bpm vs +4–6 bpm on retatrutide
Cheapest per kg lost?
Retatrutide
Only via research-grade channels; not a fair comparison vs prescription tirzepatide

The clean read: tirzepatide if you want a fully-approved, insurance-friendly path with cardiovascular data already in the books. Retatrutide if maximum weight loss, faster results, liver fat, or lean-mass preservation outweigh the regulatory uncertainty.

A third contender is now in Phase 3: VK2735, a dual GLP-1/GIP agonist that reported 14.7% weight loss by injection and 12.2% as a daily tablet over 13 weeks.

Frequently Asked Questions

Does retatrutide or tirzepatide cause more hair loss?
Neither drug causes hair loss directly — it's a telogen effluvium response to rapid weight loss, the same pattern seen with semaglutide. Risk scales with how fast you're losing weight, not which drug you're on. Because retatrutide produces faster, larger weight loss, hair shedding tends to be more common and more pronounced on retatrutide than tirzepatide, even though the mechanism is identical. Both resolve on their own within 3–6 months of the shedding phase ending. Hitting 1.2–1.6 g/kg protein daily and slowing the rate of loss are the two interventions that actually help.
Which is cheaper: retatrutide or tirzepatide?
Through pharmacy channels, tirzepatide wins on price because retatrutide isn't FDA-approved yet — there's no retail or insurance pathway for retatrutide. Tirzepatide costs ~$25–550/month with insurance, $299–449/month via LillyDirect (Zepbound, October 2026), or ~$200–400/month for compounded. Retatrutide is only sold research-grade by peptide vendors (Ascension R-30: $250, or $125 with code PEPTIDEDECK); FDA says it can't be compounded, so telehealth "compounded retatrutide" is not a legal product. On a per-kilogram-lost basis, research-grade retatrutide is the cheapest option overall, but that comes without clinical oversight or regulatory protection.
Is retatrutide better than tirzepatide?
For raw weight loss, yes: retatrutide produces approximately 4-6 percentage points more weight loss on average based on available trial data (28.3% vs 22.5% among people who stayed on treatment, 25.0% vs 20.9% counting everyone, at maximum doses). It also has advantages in liver fat reduction and lean mass preservation due to the glucagon receptor component. However, tirzepatide is FDA-approved and commercially available today, backed by extensive real-world data and cardiovascular outcome trial results. Retatrutide is better on efficacy; tirzepatide is the better choice for accessibility and regulatory certainty in 2026.
What is the difference between retatrutide and tirzepatide?
Tirzepatide activates two hormone receptors: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and the glucagon receptor. The glucagon receptor is the key differentiator, it increases energy expenditure, promotes fat oxidation, reduces liver fat, and may help preserve lean muscle during weight loss. Both drugs are once-weekly subcutaneous injections, both cause significant GI side effects during dose escalation, and both share the same class-level black box warning for thyroid C-cell tumors.
Can you switch from tirzepatide to retatrutide?
Yes. The standard approach is to take your last tirzepatide dose, wait one week, then start retatrutide at 2 mg and escalate on the standard schedule regardless of what tirzepatide dose you were on. Do not attempt to dose-match between compounds, they have different potency profiles. Most people who were fully adapted to tirzepatide experience some GI re-adjustment in the first 2-4 weeks on retatrutide, which is expected and usually resolves.
When will retatrutide be FDA approved?
Not before late 2027. TRIUMPH-4 reported in December 2025 and TRIUMPH-1, -2 and -3 in 2026, but Lilly plans to submit to the FDA only in Q1 2027, and a review typically takes 10–12 months, so approval is more likely in 2028. There are no guarantees on timing. Until approval, retatrutide is not commercially available through standard pharmacy channels in the US.
Does retatrutide cause more side effects than tirzepatide?
Generally yes, particularly on GI symptoms and heart rate elevation. Retatrutide's higher potency and the addition of glucagon receptor activation both contribute to a slightly more demanding side effect profile, especially during dose escalation. Nausea and vomiting rates are higher at equivalent weight-loss doses. Heart rate elevation averages 4-6 bpm on retatrutide vs 2-4 bpm on tirzepatide. Both are manageable with proper slow escalation; the difference is meaningful but not a reason to avoid retatrutide if the weight loss advantage is your priority.
What does the TRIUMPH-4 trial show?
TRIUMPH-4 is a Phase 3 trial of retatrutide in people with obesity and knee osteoarthritis; the main obesity trial is TRIUMPH-1. Topline results released in December 2025 showed 28.7% average body weight reduction at the highest dose over 68 weeks, among people who stayed on treatment. This represents the largest weight loss ever recorded for a pharmaceutical agent in a Phase 3 trial, surpassing tirzepatide's SURMOUNT results (20.9% at 72 weeks) and semaglutide's STEP results (~15-17%). Full TRIUMPH-4 results have not yet been published in a journal, and nothing has been submitted to the FDA yet; Lilly plans to file in Q1 2027.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Retatrutide is not FDA-approved. Tirzepatide requires a prescription. Always consult a qualified healthcare provider before starting any weight loss medication. PeptideDeck may earn a commission from affiliate links at no additional cost to you.
Retatrutide - R-30

Recommended Supplier

In StockShips from USA

Retatrutide - R-30

R-30 from Ascension Peptides, third-party tested and shipped from the US.

$125.00$250.00Save $125.00

Exclusive 50% off — use code PEPTIDEDECK

Related Topics

retatrutidetirzepatideglp-1weight losscomparisontriple agonist